



China has demonstrated to be one of the ideal R&D outsourcing countries, with the advantages of its lower costs and excellent human resources. Chemistry service in China has been a greatly successful story for helping western pharmaceutical companies. However, most western pharmaceutical industries are hesitant to move pre-clinical drug evaluations to China. Currently, several animal facilities in China have passed AAALAC accreditation and are offering preclinical pharmacokinetics and pharmacology services along with GLP toxicological services (ADMET services). In this presentation, the current status for preclinical PK/PD services in China will be discussed.

## Current Status for Preclinical PK/PD Services in China

Chunlin Chen, Ph.D.

陈春麟博士, CEO, Shanghai Medicilon Inc.

上海药理学学会药物代谢动力学专业委员会副主任委员

上海浦东生物医药学会副理事长

中国药科大学生命科学院客座教授

Time: 6:30~9:30 pm, Tues, Nov 10, 2009

Place: Empress Pavilion Restaurant (汉宫)

988 N. Hill Street, Los Angeles, CA 90012  
(213) 617-9898; [www.empresspavilion.com](http://www.empresspavilion.com)

Fees: Students \$20; Others \$50

On-site registration only

Contact: Prof. Jeffrey Wang

Phone: (626) 348-9036

Sponsored by  
American Chinese Pharmaceutical  
Association (ACPA)

